RESEARCH Open Access Combined PD-1 blockade and GITR triggering

1Department of Surgical Oncology, Jindu Hospital, Nanjing 210002, Chinaefficacy with 80 % of mice obtaining tumor-free long-term survival in murine ID8 ovarian cancer and 4 T1 breast cancer models. Conclusions: Combined anti-PD-1/GITR mAb treatment induces a potent antitumor immunity, which can be further promoted by chemotherapeutic drugs. A combined strategy of anti-PD-1/GITR mAb plus cisplatin or paclitaxel should be considered translation into clinic